Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No. That would be absolutely ludicrous for a public company to allow share count visibility to that level - which would show timing of 105b-1 buybacks, repurchases during windows & blackout periods, etc. No public company does that. That is the accepted standard. I'd be interested in just one company that allows intra-quarter share count insights. The TA would ask for a client ID that ONLY CFO & IR would know. That is the norm. They may provide insight as of the most recent Q, but not intra-quarter.
Wong be long? Is that a secret wish? Lol
No TA does. That is their job to keep it confidential.
You are correct that it is fact, but large percentage growth on small numbers is the issue. Another fact to throw out is why hasn't revenue grown sequentially quarter to quarter? A growth company focuses more on sequential growth than year/year.
HOD was .157. Some tape painting st the end of the day. Took me almost 3 hours to get my order filled today.
But can be abused by swallowing. Forgot to note that caveat.
Yes, exchange does matter but more so do the shares outstanding: 46M vs 925M
That is laughable and completely untrue. If Elite get's 5% market share where do you think the remaining 95% is going?
Existing products have 100% of sales today. One cannot exclude them from future competition. Completely illogical.
Garbage. He said over a year ago that a RS would at least be a year out. We are now within that feasible window.
Funny how there is the exclusion of 100% of the drugs currently in those markets today. Can't exclude all competition. Completely unrealistic.
My comment was one of sarcasm & yet confusion. Lol
And why is there poop on nuts?!
Pure garbage. For anyone that can read financial statements the profitability was fake and not from operations. Will 2017 be different? Probably not, but 2018 has a shot.
Epic actually had decent revenue and profit fr a public company. Elite does not.
Elite doesn't as of today either. Glad I could clear up the BS.
Let me help you out here. There are 6 companies that have approved generic versions of OxyContin (brand name for oxycodone):
1) Teva
2) Actavis
3) Impax
4) Sandoz
5) Par
6) Lake Erie Medical
Sounds as accurate as often claimed Aug 2015 slam dunk approval.
We're any insider buys at the market or just grants?
Historical avg going back to WWII is closer to 13%.
Until there is an approval, the current generics are worth much much more.
I was disappointed Elite didn't get the Adcom to hear other challenges/concerns. Would have been interesting dialogue. We'll see how FDA reacts. Wouldn't be first time doing opposite of Adcom recommendation if they go that route.
Wow, very interesting. Seeing Elite was prevented from having an Adcom.
To get on NASDAQ there are certain requirements.
The very valid point is being glossed over. That is not how many insurance programs work today as more risk each year is placed on the consumer. Ever expanding deductibles are burning holes in wallets before insurance pays a dime. I used to work in the insurance industry and the trends are frightening.
That list keeps decreasing. It was 10, then 7, now 6. Do I hear 4 next week?
IR confirmed submission by end of the calendar year. This is not news. Your timeline is correct, but was already known.
Clueless
If you are insinuating Elite's TA is different, which is not the case. It is just like every other public company. If they were gagged they wouldn't even admit that they are Elite's TA.
That comment is 100% baseless. CEO himself stated it is on the table. Why deny his own words?
I called the TA myself. They provide all the same info that any TA provides on a public company. No TA provides the outstanding share count unless you are a management insider. This is completely normal.
May not be imminent, but CEO stated it is an option in about a year (he said over a year ago). If pipeline doesn't start getting approved, it is for sure going to happen. Depends entirely on how quickly the FDA acts.
Proving efficacy is one of aspects new FDA chief will remove. Yes, Elite has proved efficacy, but if the market is flooded with other drugs that don't have to prove efficacy that is what will cause confusion.
With the ringer Elite is being put through for approval, getting rid of this will only harm Elite if efficacy doesn't need to be proven. That causes significant confusion and would harm potential future prospects.
New proposed FDA chief sounds exactly like a Califf v2.0 with deep ties to big pharma. Remember how that turned out for SequestOx in December?
Nasrat has made commentary about selling, but until we have an FDA approval we have zero leverage in conversations. Until those approvals start rolling in we are stuck near 52-week lows.
You don't value this company on PE. Earnings last quarter were not operationally driven. Valuation is completely based on potential approved tech & associated pipeline.
When/if approval is given that will be a different day.
Perc too? Wow, totally missed that too or have a serious memory relapse.
Got it, thanks. That is how I initially interpreted your comment and then confused myself.